AR039842A1 - Compuestos heterociclicos sustituidos y metodos de empleo - Google Patents
Compuestos heterociclicos sustituidos y metodos de empleoInfo
- Publication number
- AR039842A1 AR039842A1 ARP030101777A ARP030101777A AR039842A1 AR 039842 A1 AR039842 A1 AR 039842A1 AR P030101777 A ARP030101777 A AR P030101777A AR P030101777 A ARP030101777 A AR P030101777A AR 039842 A1 AR039842 A1 AR 039842A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- substituted
- independently
- instance
- nrgrg
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Reivindicación 1: Un compuesto de la fórmula (1) o una de sus sales farmacéuticamente aceptable, donde: n es 0, 1 ó 2; R1 es una cadena cerrada de 5, 6 ó 7 miembros, saturada o insaturada, que contiene 0, 1, 2 ó 3 átomos seleccionados de N, O y S, donde la cadena cerrada puede estar fusionada con un grupo benzo, y está sustituida por 0, 1 ó 2 grupos oxo, y donde R1 está adicionalmente sustituido por 0, 1, 2 ó 3 sustituyentes seleccionados de Rd y alquilo C1-4Rd; R2 es alquilo C1-6 sustituido con 1, 2 ó 3 grupos Rd y 0 ó 1 grupos Rc, que están sustituidos por 0, 1 ó 2 grupos Rd, donde R2 no es -C(=O)Obencilo; y donde -R1-R2 no es 3-bencilpiperazin-1-ilo; y donde si tanto R3 como R4 son 4-metilfenilo, -R1-R2 no es 4-(hidroximetil)piperidin-1-ilo; R3 es Rc sustituido por 0, 1, 2 ó 3 sustituyentes seleccionados de Rf y Rd; R4 es Rc sustituido por 0, 1, 2 ó 3 sustituyentes seleccionados de Rf y Rd que no incluyen 1-feniletilamino; siempre que el número total de grupos Rc sustituidos en cada uno de R3 y R4 sea 0 ó 1; R5 es independientemente en cada instancia H, alquilo C1-8 o alquilo C1-6Rc, ambos sustituidos por 0, 1, 2 ó 3 sustituyentes seleccionados de Rd; R6 es independientemente en cada instancia alquilo C1-8 o alquilo C1-6Rc, ambos sustituidos por 0, 1, 2 ó 3 sustituyentes seleccionados de Rd; o R6 es Rd; R7 es independientemente hidrógeno, -alquilo C1-6 o -alquilo C1-4Rc, donde cualquier átomo de carbono de la estructura anterior está sustituido por 0 a 3 sustituyentes seleccionados de Rd; Ra es independientemente en cada instancia h O Rb; Rb es independientemente en cada instancia alquilo C1-8, Rc o alquilo C1-4Rc, cada uno de los cuales está sustituido por 0, 1, 2 ó 3 sustituyentes seleccionados independientemente de Rd; Rc es independientemente en cada instancia arilo o una cadena cerrada heterocíclica de 5, 6 ó 7 miembros saturado o insaturada, que contiene 1, 2 ó 3 átomos seleccionados de N, O y S, donde la cadena cerrada está fusionada con 0 ó 1 grupos benzo y 0 ó 1 cadenas cerradas heterocíclicas de 5, 6 ó 7 miembros, saturadas o insaturadas, que contienen 1, 2 ó 3 átomos seleccionados de N, O y S; donde cualquier cadena cerrada heterocíclica está sustituida por 0, 1 ó 2 grupos oxo; Rd es independientemente en cada instancia alquilo C1-6, halo, haloalquilo C1-4, ciano, -C(=O)Rf, -C(=O)ORe, -C(=O)NRgRg, -C(=NRg)NRgRg, -ORe, --OC(=O)Re, -OC(=O)NRgRg, -OC(=O)N(Rh)S(=O)2Rf, -SRe, -S(=O)Rf, -S(=O)2Rf, -S(=O)2NRgRg, -S(=O)2N(Rh)C(=O)Rf, -S(=O)2N(Rh)C(=O)ORf, -S(=O)2-N(Rh)C(=O)NRgRg, -NRgRg, -N(Rh)C(=O)Re, -N(Rh)C(=O)ORf, -N(Rh)C(=O)NRgRg, -N(Rh)C(=NRg)NRgRg, -N(Rh)S(=O)2Rf ó -N(Rh)S(=O)NRgRg; Re es independientemente en cada instancia hidrógeno o Rf; Rf es independientemente en cada instancia Rc o alquilo C1-8, cualquiera de los cuales está sustituido por 0 a 3 sustituyentes seleccionados de -NRgRg, -C(=O)ORi, -ORi,-N(Ri)C(=O)Rk, -N(Ri)C(=O)ORi, -N(Ri)S(=O)2Rk, -S(=O)nRk, ciano, halo, -O alquilo C1-4 Rc, -S(=O)n alquilo C1-4 Rc y Rc, donde cualquier Rc en Rf puede estar sustituido, también, por alquilo C1-8 o haloalquilo C1-4; Rg es independientemente en cada instancia hidrógeno, Rc, alquilo C1-10 o -alquilo C1-4Rc, donde cada uno está sustituido por 0 a 3 sustituyentes seleccionados de -NRiRi, -N(Ri)C(=O)Rk, -N(Ri)C(=O)ORk, -N(Ri)S(=O)2Rk, -ORi, -S(=O)nRk, ciano, alquilo C1-8 y haloalquilo C1-4; Rh independientemente en cada instancia hidrógeno, alquilo C1-8 o alquilo C1-4Rc cada uno de los cuales está sustituido por 0 a 3 sustituyentes seleccionados de -NRiRi, -N(Ri)C(=O)Rk, -N(Ri)C(=O)ORk, -N(Ri)S(=O)2Rk, -ORi, -S(=O)nRk, ciano, alquilo C1-8 y haloalquilo C1-4; Ri es Rk o hidrógeno; Rk es alquilo C1-6, fenilo o bencilo; V es -N=, -NR5-, -CR6=, C=O, C=S o C=NR7; W es -N=, -NR5-, -CR6=, C=O, C=S o C=NR7; y X es -N=, -NR5-, -CR6=, C=O, C=S o C=NR7; donde el número total de grupos -NR5-, C=O, C=S o C=NR7 representados por V, W y X debe ser 0 ó 2; y al menos uno de V, W y X contiene un átomo de N. También se incluye un método para la profilaxis o el tratamiento de: inflamación, artritis reumatoidea, mal de Paget, osteoporosis, mieloma múltiple, uveitis, leucemia mielógeno aguda o crónica, destrucción de las células beta pancreáticas, osteoartritis, espondilitis reumatoidea, artiritis gotosa, enfermedad inflamatoria intestinal, síndrome de distrés respiratorio del adulto [ARDS, por sus siglas en inglés], soriasis, enfermedad de Crohn, rinitis alérgica, colitis ulcerosa, anafilaxis, dermatitis por contacto, asma, degeneración muscular, caquexia, síndrome de Reiter, diabetes del tipo I y del tipo II, enfermedades relacionadas con la resorción ósea, reacción injerto contra huésped, Mal de Alzheimer, ataque cerebrovascular, infarto del miocardio, lesión por isquemia-reperfusión, ateroesclerosis, trauma cerebral, esclerosis múltiple, malaria cerebral, sepsis, choque séptico, síndrome de choque tóxico, fiebre, mialgias padecidas a raíz de infecciones por VIH-1, VIH-2, VIH-3, citomegalovirus [CMV], gripe, adenovirus, herpes viral o infección por herpes zóster en un mamífero, que comprende la administración de una cantidad eficaz de un compuesto tal como el que se describió previamente.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38269902P | 2002-05-21 | 2002-05-21 | |
US10/438,553 US7026326B2 (en) | 2002-05-21 | 2003-05-13 | Substituted heterocyclic compounds and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
AR039842A1 true AR039842A1 (es) | 2005-03-02 |
Family
ID=29584444
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP030101777A AR039842A1 (es) | 2002-05-21 | 2003-05-22 | Compuestos heterociclicos sustituidos y metodos de empleo |
Country Status (10)
Country | Link |
---|---|
US (1) | US7026326B2 (es) |
EP (1) | EP1506186A1 (es) |
JP (2) | JP4606161B2 (es) |
AR (1) | AR039842A1 (es) |
AU (1) | AU2003234628B2 (es) |
CA (1) | CA2485166A1 (es) |
MX (1) | MXPA04011470A (es) |
PL (1) | PL376575A1 (es) |
TW (1) | TW200406399A (es) |
WO (1) | WO2003099808A1 (es) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2533684A1 (en) * | 2003-07-25 | 2005-02-10 | Amgen Inc. | Substituted pyridones and pyrimidinones with antiinflammatory properties |
US7429594B2 (en) | 2003-08-20 | 2008-09-30 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
US20080312281A1 (en) * | 2004-12-24 | 2008-12-18 | Matthew Colin Thor Fyfe | G-Protein Coupled Receptor (Gpr116) Agonists and Use Thereof for Treating Obesity and Diabetes |
AR059898A1 (es) | 2006-03-15 | 2008-05-07 | Janssen Pharmaceutica Nv | Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2 |
US8062824B2 (en) * | 2006-07-17 | 2011-11-22 | E. I. Du Pont De Nemours And Company | Thermally imageable dielectric layers, thermal transfer donors and receivers |
US7528448B2 (en) * | 2006-07-17 | 2009-05-05 | E.I. Du Pont De Nemours And Company | Thin film transistor comprising novel conductor and dielectric compositions |
TW200845978A (en) | 2007-03-07 | 2008-12-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
TW200900065A (en) | 2007-03-07 | 2009-01-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives |
CN101801951B (zh) | 2007-09-14 | 2013-11-13 | 杨森制药有限公司 | 1’,3’-二取代的-4-苯基-3,4,5,6-四氢-2h,1’h-[1,4’]二吡啶-2’-酮 |
US7666567B2 (en) | 2007-10-23 | 2010-02-23 | E. I. Du Pont De Nemours And Company | Negative imaging method for providing a patterned metal layer having high conductivity |
US7666568B2 (en) * | 2007-10-23 | 2010-02-23 | E. I. Du Pont De Nemours And Company | Composition and method for providing a patterned metal layer having high conductivity |
RU2510396C2 (ru) | 2008-09-02 | 2014-03-27 | Янссен Фармасьютикалз, Инк. | 3-азабицикло[3.1.0]гексильные производные в качестве модуляторов метаботропных глутаматных рецепторов |
AU2009319387B2 (en) | 2008-11-28 | 2012-05-10 | Addex Pharma S.A. | Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors |
JP5707390B2 (ja) | 2009-05-12 | 2015-04-30 | ジャンセン ファーマシューティカルズ, インコーポレイテッド | 1,2,4−トリアゾロ[4,3−a]ピリジン誘導体およびmGluR2受容体の正のアロステリック調節因子としてのその使用 |
RS53075B (en) | 2009-05-12 | 2014-04-30 | Janssen Pharmaceuticals Inc. | 1,2,4-TRIAZOLO [4,3-A] PYRIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OR PREVENTION OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS |
MY153913A (en) | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
EP2661435B1 (en) | 2010-11-08 | 2015-08-19 | Janssen Pharmaceuticals, Inc. | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS |
EP2649069B1 (en) | 2010-11-08 | 2015-08-26 | Janssen Pharmaceuticals, Inc. | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS |
EP2643320B1 (en) | 2010-11-08 | 2015-03-04 | Janssen Pharmaceuticals, Inc. | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS |
ES2543050T3 (es) | 2011-02-28 | 2015-08-14 | Array Biopharma, Inc. | Inhibidores de serina/treonina quinasa |
US9187462B2 (en) | 2011-08-04 | 2015-11-17 | Array Biopharma Inc. | Substituted quinazolines as serine/threonine kinase inhibitors |
EP2773207B1 (en) * | 2011-10-31 | 2018-03-07 | Merck Sharp & Dohme Corp. | Aminopyrimidinones as interleukin receptor-associated kinase inhibitors |
US10531655B2 (en) | 2011-12-02 | 2020-01-14 | The Regents Of The University Of California | Reperfusion protection solution and uses thereof |
SI2820009T1 (en) * | 2012-03-01 | 2018-05-31 | Array Biopharma, Inc. | Serine / Threonine kinase inhibitors |
BR112015004548A2 (pt) | 2012-08-27 | 2017-08-08 | Array Biopharma Inc | inibidores de serina/treonina para tratamento de doenças hiperproliferativas |
JO3368B1 (ar) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2 |
JO3367B1 (ar) | 2013-09-06 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2 |
DK3431106T3 (da) | 2014-01-21 | 2021-03-15 | Janssen Pharmaceutica Nv | Kombinationer omfattende positive allosteriske modulatorer eller orthosteriske agonister af metabotrop glutamaterg subtype 2-receptor og anvendelse af disse |
ES2860298T3 (es) | 2014-01-21 | 2021-10-04 | Janssen Pharmaceutica Nv | Combinaciones que comprenden moduladores alostéricos positivos del receptor glutamatérgico metabotrópico de subtipo 2 y su uso |
MY190386A (en) | 2017-04-11 | 2022-04-20 | Mitsui Chemicals Agro Inc | Pyridone compounds and agricultural and horticultural fungicides containing the same as active ingredients |
ES2910839T3 (es) * | 2017-08-23 | 2022-05-13 | Sprint Bioscience Ab | Compuestos de piridilpiridona |
US11208423B2 (en) * | 2017-08-23 | 2021-12-28 | Sprint Bioscience Ab | Pyridinamine-pyridone and pyrimidinamine- pyridone compounds |
CN117083064A (zh) | 2020-11-25 | 2023-11-17 | 德西费拉制药有限责任公司 | 作为vps34抑制剂用于治疗病毒感染的吡啶基吡啶酮衍生物 |
WO2023156386A2 (en) * | 2022-02-16 | 2023-08-24 | Duke Street Bio Limited | Pharmaceutical compound |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2602794A (en) * | 1952-07-08 | Process for preparation of x-amino-s | ||
WO1995009917A1 (en) | 1993-10-07 | 1995-04-13 | The Regents Of The University Of California | Genetically engineered bispecific tetravalent antibodies |
CA2205572A1 (en) | 1994-12-12 | 1996-06-20 | Beth Israel Hospital Association | Chimeric cytokines and uses thereof |
NZ503548A (en) | 1996-02-09 | 2001-09-28 | Amgen Inc | A fusion protein comprising an IL-1ra receptor antagonist with a constant domain of human immunoglobulin at the carboxy terminus |
US6100071A (en) | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
US6096753A (en) * | 1996-12-05 | 2000-08-01 | Amgen Inc. | Substituted pyrimidinone and pyridone compounds and methods of use |
US6410729B1 (en) * | 1996-12-05 | 2002-06-25 | Amgen Inc. | Substituted pyrimidine compounds and methods of use |
TW520362B (en) * | 1996-12-05 | 2003-02-11 | Amgen Inc | Substituted pyrimidine compounds and pharmaceutical composition comprising same |
EP0948496A2 (en) * | 1996-12-05 | 1999-10-13 | Amgen inc. | Substituted pyrimidinone and pyridone compounds and methods of use |
EP2002846B1 (en) | 1996-12-06 | 2017-01-25 | Amgen Inc. | Combination therapy using an IL-1 inhibitor for treating IL-1 mediated diseases |
KR19980066046A (ko) | 1997-01-18 | 1998-10-15 | 정용훈 | 고역가의 CTLA4-Ig 융합단백질 |
ES2183351T3 (es) | 1997-04-17 | 2003-03-16 | Amgen Inc | Composicones que comprenden conjugados de proteina ob humana activa estable con una cadena fc de inmunoglobulinas y metodos. |
NZ528409A (en) * | 2001-03-15 | 2005-11-25 | Basf Ag | 5-phenylpyrimidine, methods and intermediate products for the production thereof and use of the same for controlling pathogenic fungi |
-
2003
- 2003-05-13 CA CA002485166A patent/CA2485166A1/en not_active Abandoned
- 2003-05-13 US US10/438,553 patent/US7026326B2/en not_active Expired - Lifetime
- 2003-05-13 WO PCT/US2003/015473 patent/WO2003099808A1/en active Search and Examination
- 2003-05-13 MX MXPA04011470A patent/MXPA04011470A/es active IP Right Grant
- 2003-05-13 AU AU2003234628A patent/AU2003234628B2/en not_active Ceased
- 2003-05-13 JP JP2004507465A patent/JP4606161B2/ja not_active Expired - Fee Related
- 2003-05-15 EP EP03728971A patent/EP1506186A1/en not_active Withdrawn
- 2003-05-15 PL PL376575A patent/PL376575A1/pl not_active Application Discontinuation
- 2003-05-21 TW TW092113725A patent/TW200406399A/zh unknown
- 2003-05-22 AR ARP030101777A patent/AR039842A1/es not_active Application Discontinuation
-
2010
- 2010-07-09 JP JP2010157000A patent/JP2010280669A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
JP2005530810A (ja) | 2005-10-13 |
US20050038010A1 (en) | 2005-02-17 |
EP1506186A1 (en) | 2005-02-16 |
WO2003099808A1 (en) | 2003-12-04 |
AU2003234628B2 (en) | 2007-08-23 |
JP4606161B2 (ja) | 2011-01-05 |
MXPA04011470A (es) | 2005-02-14 |
PL376575A1 (pl) | 2006-01-09 |
WO2003099808A8 (en) | 2009-02-05 |
TW200406399A (en) | 2004-05-01 |
AU2003234628A1 (en) | 2003-12-12 |
CA2485166A1 (en) | 2003-12-04 |
JP2010280669A (ja) | 2010-12-16 |
US7026326B2 (en) | 2006-04-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR039842A1 (es) | Compuestos heterociclicos sustituidos y metodos de empleo | |
KR101968058B1 (ko) | 지질 합성의 헤테로사이클릭 조절자 | |
BR112020018610A2 (pt) | Compostos de fórmula i, fórmula ii, fórmula iii, fórmula iv, fórmula v, fórmula vi, ou seus polimorfos, estereoisômeros, tautômeros, profármacos, solvatos e sais farmaceuticamente aceitáveis dos mesmos e uso dos mesmos; processo de preparação; composição farmacêutica; e método para o tratamento e/ou prevenção de várias doenças, que incluem câncer e doenças infecciosas | |
CA3055867C (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
NO20076185L (no) | 2-amido-6-amino-8-oksopurinderivater som "Toll-like receptor" modulatorer for behandling av cancer og virale infeksjoner slik som hepatitt C | |
PE20141010A1 (es) | Derivados de piridin-2(1h)-ona utiles como medicamentos para el tratamiento de transtornos mieloproliferativos, rechazo de transplantes, enfermedades mediadas por el sistema inmune y enfermedades inflamatorias | |
AU612350B2 (en) | Novel thiazole derivatives active on the cholinergic system, process for obtention and pharmaceutical compositions | |
AR042192A1 (es) | Derivados antivirales de nucleosidos de pirimidina | |
HUP0402065A2 (hu) | Heterobiciklikus szerkezetû hepatitis C vírus polimeráz inhibitorok, eljárás az elõállításukra és ezeket tartalmazó gyógyszerkészítmények | |
JP2007530598A5 (es) | ||
RU2008133382A (ru) | Соединения гидантоина для лечения воспалительных заболеваний | |
WO2010053438A1 (en) | Modulators of amyloid beta. | |
CA2682473A1 (en) | Novel pyrrolinone derivative and pharmaceutical composition comprising the same | |
JP6372666B2 (ja) | サイトメガロウイルスの阻害剤 | |
AR054208A1 (es) | Derivados de oxopiperidina, su preparacion, una composicion farmaceutica y compuestos intermediarios | |
JP6567505B2 (ja) | キナゾリン誘導体およびdnaメチルトランスフェラーゼ阻害剤としてのその使用 | |
AR078321A1 (es) | Derivados de 2,4'-bipiridina como inhibidores de cinasa (cdk9) | |
PE20220252A1 (es) | Compuestos de pirrol | |
CA2488761A1 (en) | 2-benzofuryl or benzothiophenyl-quinuclidinyl amides as nicotinic acetylcholine receptor inhibitors | |
AR040253A1 (es) | Fluorobenzamidas, procesos de preparacion y medicamento | |
KR20090029182A (ko) | 단백질 키나제 억제제로서 티아졸릴디하이드로인다졸 유도체 | |
HK1094890A1 (en) | Substituted heterocyclic compounds and methods of use | |
HUP0001698A2 (hu) | Szubsztituált pirimidinszármazékok és ezeket tartalmazó gyógyászati készítmények | |
ATE355839T1 (de) | 1,4,5-substituierte 1,2-dihydro-pyrazol-3-one and 3-alkoxy-1h-pyrazole derivate als tnf-alpha und interleukin senkende wirkstoffe zur behandlung von entzündungen | |
WO2016073659A1 (en) | Process for preparing substituted indole compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |